A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)

Sex: All

Ages: 24 Years – 60 Years

Healthy volunteers: Yes

Phase: PHASE1

Enrollment: 28

Sponsor: Merck Sharp & Dohme LLC

Summary

The main goals of this study are: * To learn what happens to one dose of MK-2828 in a healthy person's body over time when it is taken with itraconzole * To learn what happens to one dose of midazolam in a healthy person's body over time when it is taken with MK-2828 Researchers want to learn if the levels of MK-2828 in the body are about the same when MK-2828 is taken with itraconazole as when it is taken alone. They also want to know if taking MK-2828 more than once affects how much midazolam is in the body after a single dose.

Eligibility Criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: \- Participant is in good health Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of cancer (malignancy) * History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07435194). StuddyBuddy aggregates publicly available trial information.